Lyudmila Bazhenova, MD

Lyudmila Bazhenova, MD, discusses the FDA’s expanded approval of taletrectinib for ROS1-positive non–small cell lung cancer.

Lyudmila Bazhenova, MD, explains why the updated taletrectinib label does not change her practice and reviews new WCLC subgroup data in ROS1+ NSCLC.

Explore how taletrectinib's CNS penetration may delay brain metastases and reduce the need for radiation in non–small cell lung cancer patients with ROS1.